Like most have been trying to think through recent events. After putting aside the good news - bad news - here are my thoughts. This will be the last dilution. Ariad will never be involved in the marketing of Ponatinib. The company will be sold as more of the value is proved. The timing - probably within 18 months. Ponatinib will weigh heavily in the price because part of the value of Ridaforolimus has already been sold via the advanced payments. My preliminary estimate $700 million - $1billion.